Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) has recently announced that it has signed a license and co-development contract with Ildong Pharmaceutical for Arena’s internally invented inverse agonist of the serotonin 2A receptor, temanogrel. The contract approves Ildong with exclusive rights to commercialize temanogrel in South Korea for acute coronary syndrome, peripheral artery disease, myocardial infraction, stroke and other cardiovascular diseases that are subject to further development and regulatory support for temanogrel.
In the starting, Ildong will be in charge of financing and conducting the nest two strategic clinical trials in this program under the supervision of a joint steering committee.
Arena’s President and CEO, Jack Lief said that the Phase 1 trials Arena initially conducted to support temanogrel’s prospects to treat a variety of conditions that are related to thrombosis through a novel mechanism capable of providing benefits over presently available therapies. He feels a successful product in the category can serves as an exceptional treatment option for a number of patients and this collaboration with Ildong will be enabling Arena to recommence clinical development in a low-cost mode.
Arena will maintain its ownership of temanogrel beyond the barriers of South Korea and it will reserve the rights to use data produced by Ildong for the development and potential commercialization of temanogrel outside South Korea. Additionally, Ildong has agreed to pay $2 million development milestone if the planned additional Phase 1 and Phase 2a clinical trials executed by Ildong support development and Arena or an Arena licensee starts a Phase 2b clinical trial on temanogrel. Arena is also in charge of receiving a royalty on net sales of temanogrel in South Korea while Ildong is entitled to receive a share of future payments that are received by Arena associated to licensing transactions and sales on temanogrel in other parts.
Chairman and CEO of Ildong, Jung-chi Lee said that the company is happy to enter into collaboration with Arena for temanogrel.